Anticoagulant drugs: what is new?

dc.contributor.authorKei, A.en
dc.contributor.authorFlorentin, M.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorLiberopoulos, E.en
dc.date.accessioned2015-11-24T19:36:04Z
dc.date.available2015-11-24T19:36:04Z
dc.identifier.issn1827-1839-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23799
dc.rightsDefault Licence-
dc.subjectAdministration, Oralen
dc.subjectAnimalsen
dc.subjectAnticoagulants/administration & dosage/adverseen
dc.subjecteffects/pharmacokinetics/*therapeutic useen
dc.subjectAntithrombins/therapeutic useen
dc.subjectBlood Coagulation/*drug effectsen
dc.subjectFactor Xa/antagonists & inhibitorsen
dc.subjectHemorrhage/chemically induceden
dc.subjectHumansen
dc.subjectRisk Assessmenten
dc.titleAnticoagulant drugs: what is new?en
heal.abstractHeparins and vitamin K antagonists have been the cornerstones of anticoagulation treatment for several decades. Despite their effectiveness, these agents have limitations which can include food and drug interactions and the need for monitoring. It follows that there is a need for new anticoagulants. There are numerous promising agents at various stages of evaluation. Those in the most advanced stages of development are the oral factor Xa and the thrombin inhibitors, which are the focus of this review.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21747349-
heal.journalNameInt Angiolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2011-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: